Sol-Gel Technologies Ltd.

$65.29+3.13%(+$1.98)
TickerSpark Score
55/100
Mixed
50
Valuation
40
Profitability
55
Growth
68
Health
60
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLGL research report →

52-Week Range64% of range
Low $6.80
Current $65.29
High $97.97

Companywww.sol-gel.com

Sol-Gel Technologies Ltd. , a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions.

CEO
Moshe Arkin
IPO
2018
Employees
34
HQ
Ness Ziona, IL

Price Chart

+737.05% · this period
$97.97$52.44$6.90May 20Nov 18May 20

Valuation

Market Cap
$183.46M
P/E
-29.69
P/S
9.46
P/B
7.97
EV/EBITDA
15.92
Div Yield
0.00%

Profitability

Gross Margin
100.00%
Op Margin
-39.16%
Net Margin
-31.60%
ROE
-24.29%
ROIC
-31.32%

Growth & Income

Revenue
$19.39M · 68.04%
Net Income
$-6,127,000 · 42.09%
EPS
$-2.20 · -478.95%
Op Income
$-7,592,000
FCF YoY
101.98%

Performance & Tape

52W High
$97.97
52W Low
$6.80
50D MA
$75.20
200D MA
$51.43
Beta
1.17
Avg Volume
38.51K

Get TickerSpark's AI analysis on SLGL

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
May 13, 26Opaleye Management Inc.buy1,937
May 12, 26Opaleye Management Inc.buy1,500
Mar 24, 26Opaleye Management Inc.buy34,665
Mar 24, 26Opaleye Management Inc.buy5,000
Mar 18, 26Yosef Itzikother2,031
Mar 18, 26Yosef Itzikother566
Mar 18, 26Yosef Itzikother499
Mar 18, 26Ben-Or Eyalother0
Mar 18, 26Ben-Or Eyalother360
Mar 18, 26Ben-Or Eyalother180

Our SLGL Coverage

We haven't published any research on SLGL yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate SLGL Report →

Similar Companies